ARTICLE | Company News

Amgen buys Dezima

September 17, 2015 1:38 AM UTC

Amgen Inc. (NASDAQ:AMGN) will acquire Dezima Pharma B.V. (Naarden, the Netherlands) for $300 million up front and up to $1.25 billion in milestones, plus potential royalties. The driver of the deal is TA-8995, a cholesteryl ester transfer protein ( CETP) inhibitor that has completed Phase IIb testing to treat dyslipidemia.

Amgen said that along with its PCSK9 inhibitor Repatha evolocumab, it will be able to offer multiple mechanisms for lowering cholesterol. ...